Optical imaging of tumor cells in hollow fibers: Evaluation of the antitumor activities of anticancer drugs and target validation

Neoplasia

Volumn 9, Issue 8, 2007, Pages 652-661

  Zhang, Guo Jun ^a   Chen, Tsing Bau ^a   Bednar, Bohumil ^a   Connolly, Brett M ^a   Hargreaves, Richard ^a   Sur, Cyrille ^a   Williams Jr , David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiogenesis; Bioluminescence imaging; Hollow fiber; NF B; Optical imaging

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LIPOPOLYSACCHARIDE; LUCIFERASE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; DRUG SCREENING; HOLLOW FIBER; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

EID: 34548289035     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07421     Document Type: Article

References (23)

1. Wang W and El-Deiry WS (2003). Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2, 196-202.
2. Uhrbom L, Nerio E, and Holland EC (2004). Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 10, 1257-1260.
3. Harada H, Kizaka-Kondoh S, and Hiraoka M (2005). Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4, 182-193.
4. Lungu GF, Li ML, Xie X, Wang LV, and Stoica G (2007). In vivo imaging and characterization of hypoxia-induced neovascularization and tumor invasion. Int J Oncol 30, 45-54.
5. Luker GD, Pica CM, Song J, Luker KE, and Piwnica-Worms D (2003). Imaging 26S proteasome activity and inhibition in living mice. Nat Med 9, 969-973.
6. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, and Kaelin WG Jr (2004). Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 10, 643-648.
7. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, and Rehemtulla A (2002). Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 99, 16551-16555.
8. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, and Grever MR (1995). In vivo cultivation of tumor cells in hollow fibers. Life Sci 57, 131-141.
9. Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, and Kerr JS (2000). The hollow fiber assay: continued characterization with novel approaches. Anticancer Res 20, 903-911.
10. Suggitt M, Swaine DJ, Pettit GR, and Bibby MC (2004). Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo. Clin Cancer Res 10, 6677-6685.
11. Sadar MD, Akopian VA, and Beraldi E (2002). Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol Cancer Ther 1, 629-637.
12. Krauthauser CM, Hall LA, Wexler RS, Slee AM, Mitra J, Enders GH, and Kerr JS (2001). Regulation of gene expression and cell growth in vivo by tetracycline using the hollow fiber assay. Anticancer Res 21, 869-872.
13. Zhang GJ, and Kaelin WG Jr (2005). Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover. Methods Enzymol 399, 530-549.
14. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, et al. (1997). Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151, 671-677.
15. Burgos JS, Rosol M, Moats RA, Khankaldyyan V, Kohn DB, Nelson MD Jr, and Laug WE (2003). Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. Biotechniques 34, 1184-1188.
16. Suggitt M and Bibby MC (2005). 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11, 971-981.
17. Phillips RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ, and Double JA (1998). Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. Cancer Res 58, 5263-5266.
18. Folkman J (2003). Angiogenesis and apoptosis. Semin Cancer Biol 13, 159-167.
19. Morse DL, Gray H, Payne CM, and Gillies RJ (2005). Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4, 1495-1504.
20. Bahadori HR, Rocha Lima CM, Green MR, and Safa AR (1999). Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 19, 5423-5428.
21. Hardman WE, Moyer MP, and Cameron IL (1999). Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer 81, 440-448.
22. Karin M and Greten FR (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5, 749-759.
23. Carlsen H, Alexander G, Austenaa LM, Ebihara K, and Blomhoff R (2004). Molecular imaging of the transcription factor NF-kappaB, a primary regulator of stress response. Mutat Res 551, 199-211.